INTRODUCTION
Muscular dystrophies (MD) are a group of debilitating, incurable, and often lethal disorders that present with many of the same pathological features (Emery, 2002) . A shared characteristic is the development of progressive skeletal muscle degeneration and weakness whose distribution can often be used to distinguish between the many forms of the disease (Duchenne, Becker, limb girdle, facioscapulohumeral, Emery-Dreifuss, myotonic dystrophy, etc.) (Emery, 1998) . Involvement of respiratory muscles and the development of reduced ventilatory function is likewise a common feature with the distribution, progression, and severity varying greatly among the different dystrophies (Mercuri and Muntoni, 2013) . Cardiac and smooth muscle can also be affected with the former manifesting as dilated cardiomyopathies and/or conduction defects and the latter presenting as problems with gastric emptying and/or urinary retention, for example (Yilmaz and Sechtem, 2012; Mercuri and Muntoni, 2013) . The primary defect in the various muscular dystrophies involves mutations of myocyte proteins important to cellular structure and/or function. These include, but are not limited to, extracellular matrix and external membrane proteins, proteins associated with the sarcolemma, sarcomeric proteins, nuclear membrane proteins and enzymatic proteins (Mercuri and Muntoni, 2013) . Despite this knowledge, the various factors that mediate the development of end-organ damage in the muscular dystrophies is not fully understood and represents an area of continued intense investigation. In this regard, the development of autonomic dysfunction in MD has received considerable attention recently.
AUTONOMIC DYSFUNCTION IN MUSCULAR DYSTROPHY
In addition to the primary muscular defects, another possible contributor to the generation of pathology in muscular dystrophy is the genesis of autonomic dysfunction. Impairments of the autonomic nervous system have been described in patients with Duchenne and Becker MD (Politano et al., 2008) . In both types of MD, an autonomic imbalance has been observed in which sympathetic activity is significantly increased coupled with diminished parasympathetic activity (Yotsukura et al., 1995; Lanza et al., 2001; Inoue et al., 2009) . It has been speculated that such an imbalance may contribute to the development of dilated cardiomyopathy, ventricular arrhythmias, and sudden cardiac death in these patients (Ducceschi et al., 1997) . In the mdx mouse model of MD, a model mimicking the abnormality found in patients with Duchenne MD (i.e., deficiency of the cytoskeletal protein dystrophin), pharmacological autonomic blockade and baroreflex sensitivity testing have likewise demonstrated an imbalance in the autonomic regulation of heart rate being characterized by enhancements and decrements in sympathetic and parasympathetic activity, respectively (Chu et al., 2002) . Similar findings have been reported in patients with facioscapulohumeral MD (DellaMarca et al., 2010) . Autonomic abnormalities of varying degrees have likewise been reported in myotonic dystrophy (Inoue et al., 1995; DiLeo et al., 2004) as well as Emery-Dreifuss (Fujita et al., 2005) , Fukuyama Congenital (Itoh et al., 1996) , and Miyoshi MDs (Tomoda et al., 1994) .
To date, most studies have focused on the impact autonomic dysfunction has on cardiac performance and morphology in MD with little attention given to its possible role in the development of skeletal myopathy (the primary pathology). Indeed, the autonomic nervous system is intimately involved in the control of blood flow to skeletal muscle via its modulation of cardiac output, blood pressure, and vascular resistance . Alterations in the ability of the autonomic nervous system to adequately regulate these hemodynamic variables could significantly compromise blood flow to peripheral skeletal muscle initiating and/or exacerbating the primary degenerative processes characteristic of the disease. As an example, normally during exercise sympathetic activity is increased while parasympathetic activity is largely withdrawn. As a result, cardiac output is enhanced and the resistance to blood flow in the visceral organs and noncontracting skeletal muscle is elevated. In contrast, sympathetic vasoconstriction is opposed in active skeletal muscle by local metabolic vasodilation (i.e., functional sympatholysis) augmenting blood flow (Remensnyder et al., 1962) . In this way, autonomic modulation of the cardiovascular system closely matches the delivery of blood to meet the metabolic demands of the working muscle. In an elegant series of studies in patients with dystrophinopathies (Duchenne and Becker MD) as well as mouse models of the disorder, it has been repeatedly demonstrated that the metabolic modulation of sympathetic vasoconstriction in working skeletal muscle is impaired producing ischemia during exercise (Thomas et al., 1998; Sander et al., 2000; Lai et al., 2009; Martin et al., 2012) . The studies indicate that this impaired function is largely due to the loss of sarcolemmal neuronal nitric oxide synthase which is requisite to produce the nitric oxide necessary to mitigate α-adrenergic vasoconstriction (Thomas et al., 1998; Sander et al., 2000) . It has been suggested that repeated bouts of ischemia in these patients, which could occur in the performance of routine daily activities, may initiate and/or accelerate fiber necrosis in the muscle (Sander et al., 2000; Ito et al., 2006) . Potentially, this could facilitate the early onset of muscle fatigue, limit exercise tolerance, and at the same time promote muscle degeneration (Thomas et al., 1998) . Although these studies do not directly infer autonomic dysfunction but rather the inability to oppose sympathetic activity, they do demonstrate the potential impact abnormal alterations in sympathetic and parasympathetic activity during exercise may have on the regulation of skeletal muscle blood flow and, potentially, the generation of skeletal myopathy in MD.
AUTONOMIC REGULATION DURING EXERCISE
Although in certain forms of MD physical activity is limited from birth, decrements in the ability to exercise present later (childhood, adolescence, adulthood) in other forms of the disease (Mercuri and Muntoni, 2013) . In patients that do maintain the ability to perform exercise, even when limited, the development of autonomic dysfunction during physical activity could have a considerable impact on the generation of both cardiac and skeletal muscle abnormalities. Therefore, it is important to understand the mechanisms underlying the autonomic response to exercise. To this end, autonomic function is regulated by input from three distinct neural mechanisms during exercise: central command, the baroreflex (arterial and cardiopulmonary) and the exercise pressor reflex. Central command has been described as a feed-forward mechanism from higher brain centers involving the parallel activation of motor neurons for volitional movement and autonomic circuits within the brainstem (Goodwin et al., 1972) . The baroreflex, with receptors located in the carotid sinuses and aortic arch (arterial baroreflex) as well as the heart and lungs (cardiopulmonary baroreflex), is a negative feedback system that modulates moment-to-moment variations in blood pressure by continually adjusting autonomic activity Mark and Mancia, 1983) . The exercise pressor reflex (EPR) is a peripheral feedback input emanating from skeletal muscle that likewise transmits signals to autonomic centers within the brainstem . Collectively, these inputs mediate precise adjustments in sympathetic and parasympathetic activity that ensure appropriate changes in blood flow are made to meet the metabolic demands of working muscle. Given that the EPR originates in skeletal muscle and is likely affected by the degenerative processes that occur with MD, it is logical to suggest that this reflex could contribute to or exacerbate autonomic dysfunction during exercise in this disease.
THE SKELETAL MUSCLE EXERCISE PRESSOR REFLEX
The EPR consists of two relatively distinct components. The afferent fibers of the first, termed the muscle mechanoreflex, consist predominately of thinly-myelinated group III (Aδ) neurons that terminate within collagen tissue between skeletal fibrocytes (Andres et al., 1985; Kaufman and Forster, 1996) . Receptors activating these afferents are largely stimulated by changes in intramuscular pressure as well as the mechanical distortion of the muscle during contraction (Stebbins et al., 1988; Williamson et al., 1994) . As such, the afferents respond immediately (within 2-5 s) at the onset of physical activity (Kaufman et al., 1983) . The associated receptors are not well defined but may include mechanogated potassium channels, L and T-type calcium channels and/or mechanogated cation channels (Hamill and McBride, 1996) . The muscle metaboreflex is the second functional component of the EPR. The afferent fibers of this reflex are primarily composed of unmyelinated Group IV (C) neurons that terminate in the walls of capillaries, venules, and lymphatic vessels within skeletal muscle (Andres et al., 1985; Kaufman and Forster, 1996) . These receptors are chemically-sensitive and stimulated by the metabolites produced during muscle work (Kniffki et al., 1978) . As a result, activation of afferent fibers associated with these receptors is somewhat delayed (5-20 s) requiring sufficient time for the production and accumulation of chemical by-products by skeletal myocytes (Kaufman et al., 1983; Mense and Stahnke, 1983) . Several chemicals have been shown to activate the metaboreflex including, but not limited to, lactic acid, potassium, bradykinin, diprotonated phosphate, analogs of adenosine triphosphate (ATP) and by-products of arachidonic acid metabolism (Rybicki et al., 1984; Stebbins and Longhurst, 1985; Rotto et al., 1989 Rotto et al., , 1990 Sinoway et al., 1994; Li et al., 2008) . In addition, several receptors have been implicated in mediating activation of associated afferent fibers such as the ATP-gated ion-channel receptor (P2X 3 ), the acid-sensing ion channel receptor (ASIC), the bradykinin receptor (B2), the transient receptor potential vanilloid 1 receptor (TRPv1), and the cannabinoid receptor (CB1) to name a few (Pan et al., 1993; Hanna et al., 2002; Li et al., 2004a; Williams et al., 2008; Smith et al., 2010) . It should be noted that both groups of afferent fibers display a degree of polymorphism with some Group III neurons responding to chemical stimuli and some Group IV neurons responding to mechanical stimuli (Kaufman and Forster, 1996) . In addition, evidence suggests that mechanically-sensitive afferents can be sensitized by metabolites (especially in the presence of low perfusion) whereas the activity of chemically-sensitive neurons is augmented during periods of muscle ischemia (Kaufman et al., 1984b) .
Most group III and IV neurons first synapse in the dorsal horn of the spinal cord in Rexed's laminae I, II, V, and X with additional evidence suggesting dense projections to lamina VI in the rostral portion of the spinal cord (Kalia et al., 1981; Panneton et al., 2005) . Several neurotransmitters and peptides are involved in conducting and modulating EPR signals in the spinal cord including glutamate, aspartate, substance P, and nitric oxide for example (Wilson et al., 1993; Hand et al., 1996; Li and Mitchell, 2002) . Likewise, a number of receptors within the spinal cord are involved in this process to variable degrees including, but not limited to, NMDA receptors, non-NMDA receptors, NK-1 receptors, and P2X receptors (Wilson, 2000) . Although not completely defined, from the dorsal horn muscle afferents travel along the dorsolateral sulcus and ventral spinal cord projecting to the cuneate nucleus, the nucleus tractus solitarius (NTS), the lateral reticular nucleus, the caudal ventrolateral medulla (CVLM), and the rostral ventrolateral medulla (RVLM) in the brain stem (Iwamoto et al., 1984; Kozelka and Wurster, 1985; Dykes and Craig, 1998; Potts et al., 2002) . Evidence suggests that the primary processing center for this afferent information is within the NTS although several other areas may also contribute including the CVLM, RVLM, the lateral tegmental field, the nucleus ambiguus and the rostral periaqueductal gray (Iwamoto et al., 1982; Iwamoto and Kaufman, 1987; Person, 1989; Li et al., 1997; Ishide et al., 2000; Li and Mitchell, 2000) . From the brainstem, parasympathetic preganglionic neurons with origins in the nucleus ambiguus travel to postganglionic neurons within the walls of the heart (Mendelowitz, 1999) . Stimulation of the EPR decreases the activity of vagal motor neurons which serves to increase heart rate. Sympathetic premotor neurons project from the brainstem to preganglionic sympathetic neurons in the intermediolateral cell columns of the spinal cord which synapse in the paraveterbral chain ganglia. Transmission of this sympathetic signal continues to postganglionic neurons that innervate the heart and vasculature (Dampney et al., 2003) . When activated, the EPR increases sympathetic nerve activity to the heart increasing its rate and contractile ability resulting in augmentations in cardiac output. Likewise, sympathetic activity to the arterial and venous circulations is concomitantly elevated mediating vasoconstriction. In short, the EPR induces autonomic adjustments to exercise by increasing sympathetic activity and largely withdrawing parasympathetic activity.
Key factors influence the magnitude of the autonomic and cardiovascular adjustments mediated by the EPR. For example, the type of muscle contraction performed effects the reflex responses produced. In general, relative tetanic contraction of skeletal muscle (e.g., static exercise) evokes a much larger increase in sympathetic activity, blood pressure, and heart rate than rhythmic contraction (e.g., dynamic exercise) (Perez-Gonzalez, 1981; Kaufman et al., 1984a) . In addition, the greater tension developed in the muscle, the greater the expression of the EPR (Iwamoto and Botterman, 1985) . The amount of muscle mass engaged likewise impacts the size of the response. In animals and humans, it has been demonstrated on several occasions that the larger the muscle mass contracted, the larger the sympathetically-mediated cardiovascular response elicited (McCloskey and Steatfield, 1975; Iwamoto and Botterman, 1985; Iellamo et al., 1999) . The fiber type of the skeletal muscle contracted also plays a role in determining the size of the evoked response. A seminal study in rabbits has demonstrated that the experimental conversion of the predominately glycolytic gastrocnemius muscle to a more oxidative fiber type significantly effects the expression of the EPR (Wilson et al., 1995) . In the investigation, contraction of the converted gastrocnemius muscle did indeed elicit elevations in blood pressure. However, these elevations were smaller in magnitude than those evoked by contraction of the un-converted gastrocnemius muscle. Thus, although contraction of Type I slow-twitch oxidative fibers increases blood pressure it does so to a lesser extent than contraction of Type II fast-twitch glycolytic fibers.
EXERCISE PRESSOR REFLEX DYSFUNCTION IN DISEASE
There is precedent for development of EPR dysfunction with the pathogenesis of disease. For example, abnormalities in EPRmediated autonomic control have been described in hypertension. Using a rat model of essential hypertension, it has been demonstrated on several occasions that preferential stimulation of the EPR elicits augmented elevations in heart rate and blood pressure resulting from exaggerated increases in sympathetic activity (Smith et al., 2006; Mizuno et al., 2011a,b) . Further research has delineated that this autonomic sympathetic dysfunction is mediated by overactivity of both functional components of the EPR (i.e., the muscle mechanoreflex and metaboreflex) (Leal et al., 2008) . The mechanisms underlying EPR overactivity in this model of hypertension remain relatively unclear although current evidence suggests that abnormalities in the expression and/or sensitivity of skeletal muscle mechanoreceptors and/or metaboreceptors may contribute significantly. Blockade of mechanoreceptors with the trivalent lanthanide gadolinium substantially mitigates the abnormally enhanced increases in sympathetic activity, blood pressure, and heart rate in response to EPR stimulation in hypertensive rats (Mizuno et al., 2011b) . Likewise, antagonism of the TRPv1 receptor (associated with the muscle metaboreflex) with capsazepine has similar effects (Mizuno et al., 2011a) . TRPv1 protein expression has also been reported to be upregulated in the dorsal root ganglia subserving the afferent fibers of the EPR (Mizuno et al., 2011a) . Alterations in the central processing of EPR afferent information may also contribute. Recent studies have shown that blocking nitric oxide production in the NTS (nitric oxide normally serves to buffer EPR activity) of normotensive rats recapitulates the mechanoreflex overactivity manifest in hypertensive animals (Leal et al., 2012) . In contrast, pharmacologically increasing nitric oxide production within the NTS of hypertensive rats abrogates mechanoreflex dysfunction (Leal et al., 2013) . As a corollary finding, neuronal nitric oxide synthase expression (the enzyme responsible for producing nitric oxide) has been shown to be reduced in areas of the NTS excited by skeletal muscle reflex input in hypertensive animals (Murphy et al., 2013) . Collectively, these studies suggest that the development of both central (brainstem) and peripheral (skeletal muscle) abnormalities contribute to EPR mediated autonomic dysfunction in essential hypertension. Interestingly, EPR dysfunction has been similarly described in other models of this disease such as prenatally programmed hypertension and angiotensin II induced hypertension (Koba et al., 2013; Mizuno et al., 2013) . With regard to the latter, increases in oxidative stress within the skeletal muscle have been shown to evoke EPR overactivity suggesting yet another peripheral mechanism by which this reflex may become dysfunctional (Koba et al., 2013) . Perhaps most importantly, exaggerations in EPR activity (specifically the metaboreflex) have recently been described in hypertensive patients verifying the pathogenesis of this disorder in humans (Sausen et al., 2009; Delaney et al., 2010) . Reports demonstrating that hypertensive individuals have a larger percentage of Type II skeletal muscle fibers as compared to Type I likely contributes significantly to the development of EPR overactivity in these patients (Juhlin-Dannfelt et al., 1979) . It is well established that chronic hypertension can induce pathological hypertrophic cardiac remodeling leading to heart failure (Takimoto et al., 2005) . Given this interrelationship, it is not surprising that autonomic regulation by the muscle reflex is likewise abnormal in this disease (Piepoli et al., 1999; Middlekauff et al., 2000; Negrao et al., 2001 ). For example, several studies have demonstrated that preferential stimulation of the EPR in rats with dilated cardiomyopathy evokes exaggerated increases in sympathetic activity resulting in abnormally large elevations in heart rate and blood pressure (Smith et al., 2003; Koba et al., 2008) . What is surprising, however, is that the etiology of EPR overactivity in heart failure appears to be different than in hypertension. As described previously, in hypertension both the mechanically and chemically sensitive components of the EPR are inappropriately augmented. In heart failure, evidence in both animals and humans suggests that EPR overactivity is primarily driven by potentiation of the mechanoreflex whereas metaboreflex function may be blunted (Sterns et al., 1991; McClain et al., 1993; Middlekauff et al., 2001; Wang et al., 2010) . With regard to the mechanoreflex, selective activation of muscle mechanoreceptors elicits enhanced increases in sympathetic activity (Li et al., 2004b; Smith et al., 2005a; Wang et al., 2010) . Research suggests this may be due to a sensitization of the mechanoreceptors by the metabolites produced during muscle contraction (Middlekauff and Chiu, 2004; Gao et al., 2007; Koba et al., 2010; Wang et al., 2010) . In support of this tenet, blockade of the B2 bradykinin receptor as well as the ATP P2X 3 receptor attenuates the cardiovascular response to EPR and mechanoreflex activation to a greater extent in cardiomyopathic rats as compared to healthy controls (Koba et al., 2010; Wang et al., 2010) . Further, P2X 3 protein expression is enhanced in the dorsal root ganglion subserving mechanosensitive afferents in heart failure animals (Gao et al., 2007; Wang et al., 2010) . Similarly, antagonizing the enzyme cyclo-oxygenase 2 (COX-2), responsible for the production of prostaglandins from arachidonic acid, reduces the sympathetic response to stimulation of the mechanoreflex to a larger degree in heart failure rats and patients than in healthy controls (Middlekauff et al., 2008; Morales et al., 2012) . COX-2 protein expression is likewise elevated in skeletal muscle of cardiomyopathic rats (Morales et al., 2012) . In contrast, the cardiovascular response to administration of metaboreceptor agonists is attenuated in heart failure (Li et al., 2004b; Smith et al., 2005b) . Interestingly, mRNA and protein expression for the TRPv1 receptor (a marker of chemicallysensitive group IV afferent fibers) is reduced in both the dorsal root ganglion and soleus muscle of heart failure rats (Smith et al., 2005b; Wang et al., 2010) . Moreover, selective ablation of group IV afferent neurons in healthy rats has been shown to recapitulate the EPR overactivity that develops in heart failure (Smith et al., 2005b) . These findings suggest that the withdrawal and/or de-sensitization of chemically-sensitive afferent fibers may contribute to the EPR dysfunction that manifests in heart failure but do not themselves drive the reflex's overactivity. These changes may occur as a result of the skeletal myopathy (conversion from Type I to Type II skeletal muscle fibers, skeletal muscle atrophy, compromised oxidative capacity) known to develop with the pathogenesis of heart failure (Lipkin et al., 1988) . Increases in oxidative stress within skeletal muscle have likewise been implicated in the generation of EPR overactivity in this disease and may play an important role in the differential mechanoreflex and metaboreflex dysfunction that manifests ).
EXERCISE PRESSOR REFLEX DYSFUNCTION IN MUSCULAR DYSTROPHY?
Whether the EPR is abnormal in MD as it is in hypertension and heart failure remains to be determined. To our knowledge, there have been no studies conducted examining the function of this reflex in the muscular dystrophies. That being stated, clearly the functional anatomy of the EPR as well as the pathophysiology it displays in cardiovascular disease demonstrates its susceptibility to dysfunction with the advent of MD. In support of this concept, other causes of muscle degeneration such as disuse atrophy have been shown to alter muscle reflex function in both animals and humans (Kamiya et al., 2004; Hayashi et al., 2005) . Further, a number of documented alterations that manifest with MD have the potential to directly influence EPR function. For example, similar to heart failure, increased expression of COX-2 and P2X protein has been demonstrated in skeletal muscle of mdx mice (Yeung et al., 2006; de Oliveira et al., 2013) . As in both hypertension and heart failure, studies suggest that oxidative stress is likewise enhanced within skeletal muscle in MD and may also be increased in the brain; the latter of which could potentially affect central EPR processing (Kaczor et al., 2007; Sabharwal and Chapleau, 2014) . As previously discussed, functional sympatholysis has been shown to be impaired in MD producing muscle ischemia during exercise (Thomas et al., 1998) . As a result, removal of exercise-induced metabolites is likely compromised. This could potentially sensitize mechanically-sensitive afferent neurons (perhaps through P2X and COX-2 pathways as in heart failure) and/or augment the activity of metabolicallysensitive sensory fibers. Collectively, these changes would favor the generation of EPR overactivity. Such overactivity could be produced by the pathogenesis of EPR dysfunction or simply evoked by overstimulation of a normally operating reflex during ischemic exercise. Changes in muscle mass could also play a significant role. As previously stated, in general MD produces widespread and profound muscle atrophy (Kornegay et al., 2012) . A loss of functional muscle mass would be expected to decrease expression of the EPR. That being stated, some muscle is spared in most forms of the disease and, in certain variations, a paradoxical hypertrophy often develops in select muscles (e.g., gastrocnemius in Duchenne and Becker MD) (Kornegay et al., 2012) . As such, expression of the reflex would likely be dependent on the muscle being contracted and the extent to which it had been affected by the disease process. Unlike hypertension and heart failure, Type II fast-twitch fibers have been shown to be preferentially affected by the dystrophic process in certain forms of MD (e.g., Duchenne MD, facioscapulohumeral MD) displaying the earliest and most pronounced deterioration (Pedemonte et al., 1999; D'Antona et al., 2007) . Type I slow-twitch fibers are affected secondarily and there is often a shift from fast-twitch to slow-twitch fibers (Webster et al., 1988; D'Antona et al., 2007) . This too would be expected to depress EPR activity. Similarly, given the structural myocyte defects that develop with MD, it is possible that skeletal muscle innervation by Group III and IV sensory neurons is compromised in the disease. To date, little is known with regard to this possibility although motor innervation of the muscle has been shown to display longitudinal displacement with some axons ending freely in connective tissue rather than muscle fibers (Coers and Telerman-Toppet, 1977) . It should be noted that the function of Group I and II sensory afferents (e.g., muscle spindles) appears to be preserved in MD (Aimonetti et al., 2005) . Whether the same is true of Group III and IV fibers remains to be determined. A theoretical depiction of the factors that could affect EPR activity in MD is presented in Figure 1 . Although largely speculative at this point, alterations in EPRmediated autonomic function in MD could significantly impact the progression of the disease. Again, metabolic modulation of sympathetically-mediated vasoconstriction during exercise is significantly diminished in certain forms of MD (i.e., impaired functional sympatholysis). This inability to buffer α-adrenergic vasoconstriction within the skeletal muscle would only be exacerbated by EPR-mediated exaggerations in sympathetic activity. This may contribute to the muscle ischemia that develops during exercise in these patients promoting tissue degeneration. Likewise, enhanced sympathetic activity to the heart evoked by the EPR could increase the risk for arrhythmogenesis, ventricular arrhythmia, and sudden death. As evidence, it has been demonstrated in rats that experimentally increasing sympathetic input to the heart can produce lethal cardiac arrhythmias (Oppenheimer et al., 1991) . Prolonged EPR dysfunction could also play a significant role in the development of the cardiomyopathy that is a common clinical feature in many muscular dystrophies. Conversely, if EPR function is diminished in MD, as is its metabolic component in heart failure, the prognosis for EPR-induced pathology may be similar although the mechanisms slightly different. Decreases in EPR function could prevent the normal vasoconstrictor responses that occur in vascular beds not involved with exercise (e.g., visceral organs, non-exercising skeletal muscle). Vasoconstriction in these beds is important for re-directing blood flow to active skeletal muscle. The net effect of such an occurrence would be much the same as when the EPR is overactive; the development of ischemia in exercising muscle. This inability to increase sympathetic activity to the heart could likewise prevent augmentations in cardiac output needed to support the adequate delivery of blood to the working muscle. It might also increase the risk for the development of bradyarrythmias which have been described in some forms of MD (e.g., myotonic dystrophy type 1) (Aminoff et al., 1985) . Undoubtedly, there is a significant need for research designed to address these possibilities.
EXERCISE TRAINING IN MUSCULAR DYSTROPHY
The benefits of exercise training are numerous and include strengthening of skeletal muscle. In addition, training has been shown to improve autonomic function in disease states in which skeletal myopathy develops. For example, aerobic exercise training has been shown to markedly improve autonomic regulation by the EPR in heart failure (Wang et al., 2012a,b) . Clearly, MD patients would benefit from improvements in both muscle strength and autonomic function. However, due to the progressive degenerative nature of the skeletal myopathy that is the hallmark feature of muscular dystrophy, patients often remain relatively sedentary and are, on many occasions, counseled to avoid excess physical activity (Sveen et al., 2008) . The rationale underlying this prescription of non-exercise is the increased probability of exercise-induced muscle damage which may accelerate the progression of the disease (Petrof, 1998) . That being stated, several reports suggest that, under the right conditions, exercise can evoke beneficial effects in certain forms of MD. For example, low intensity exercise training in mdx mice (treadmill running at 9 m/min) has been shown to reduce muscle damage caused by lipid and protein oxidation (Kaczor et al., 2007) . In patients with Becker MD, 12 weeks of cycling exercise at 65% maximal oxygen uptake (VO 2max ) has been shown to improve strength in cycling muscles as well as VO 2max without increasing markers of skeletal muscle damage (Sveen et al., 2008) . Similar beneficial effects of cycling exercise without concomitant muscle injury have been reported in patients with facioscapulohumeral MD , myotonic dystrophy , and limb-girdle type 2I MD (Sveen et al., 2007) . Likewise both low and high intensity resistance training (knee extension, elbow flexion) have been shown to increase muscle strength and endurance while being largely well tolerated in both Becker and limb-girdle type 2 MD patients (Sveen et al., 2013) . Collectively, these findings suggest that regular, supervised exercise training may be a safe beneficial therapeutic modality to use in the management of MD patients that maintains the potential to increase daily function. However, the prescription of exercise in MD remains www.frontiersin.org
February 2014 | Volume 5 | Article 47 | 5 FIGURE 1 | Theoretical model of factors that could influence exercise pressor reflex function in muscular dystrophy. During muscle contraction, the exercise pressor reflex is engaged upon stimulation of receptors which activate mechanically and metabolically sensitive afferent fibers innervating skeletal muscle. Sensory signals from these fibers are processed within autonomic control centers in the brainstem evoking decreases in parasympathetic nerve activity to the heart and increases in sympathetic nerve activity to the heart, adrenal gland, and vasculature of skeletal muscle, kidneys, and the splanchnic region. Numerous changes that occur with the pathogenesis of muscular dystrophy maintain the potential to both enhance and depress exercise pressor reflex activity. EPR, exercise pressor reflex; MD, muscular dystrophy; PSNA, parasympathetic nerve activity; SNA, sympathetic nerve activity.
controversial and warrants additional investigation. Perhaps, as has been hypothesized, there may be a threshold of exercise intensity that demarks a positive therapeutic intervention from a deleterious activity that hastens pathology (Kaczor et al., 2007) . If further research determines that changes in EPR activity contributes to and/or exacerbates autonomic dysfunction in MD, this factor must be taken into account as well when prescribing exercise.
SUMMARY
The muscular dystrophies are a group of muscle-wasting disorders that reduce quality of life and often lead to premature death. In addition to skeletal muscle, MD is known to deleteriously alter cardiac function in many forms of the disease. Recent evidence suggests that, although not the primary cause, abnormal regulation of the autonomic nervous system may contribute to the development of cardiac conduction anomalies as well as cardiomyopathy in MD. It has been postulated that such autonomic dysfunction may likewise be a causative factor in the progression of skeletal myopathy in this disease. The EPR is intimately involved in mediating the autonomic adjustments necessary to ensure the proper delivery of blood to working skeletal muscle. Given that this reflex originates in skeletal muscle, it may be vulnerable to the development of dysfunction in MD. MD-induced alterations in EPR function could compromise the reflex's ability to adequately increase blood flow to skeletal muscle during physical activity producing ischemia. Repeated bouts of ischemia during exercise could initiate and/or accelerate muscle degeneration in MD patients. Precedence for the pathogenesis of EPR dysfunction has been established in both hypertension and heart failure (a disease state often accompanied by significant skeletal myopathy) lending support to the tenet that EPR dysfunction may likewise develop in MD.
